Dr. Yaron Daniely has been the President and Chief Executive Officer and a Director of Alcobra Ltd, since March 2010. Immediately prior to joining Alcobra and since 2007, Dr. Daniely was the President and Chief Executive Officer of NanoCyte, Inc., a company that develops transdermal delivery technologies based in Caesarea, Israel. Before NanoCyte and from 2004, Dr. Daniely was the General Manager of Gamida Cell—Teva Joint Venture Ltd., a joint venture company that acquired an exclusive license to develop and commercialize a Phase 3-stage cell therapy product for treatment of Leukemia and Lymphoma based in Jerusalem, Israel. From 2003-2007, Dr. Daniely also served as the Vice President of Business Development of Gamida Cell Ltd., and engaged in several licensing and financial transactions for the Company. In addition, he co-founded and served as a director of Bioblast Ltd. (NASADQ:ORPN). Dr. Daniely holds a B.Sc. degree in Biological Sciences from Florida International University, and holds a Ph.D. from the Sackler Institute of Graduate Biomedical Sciences at the New York University School of Medicine. Following his doctoral program, Dr. Daniely served as an NIH Visiting Fellow in its Cell Biology section and a Postdoctoral Fellow in the Department of Molecular Cell Biology at The Weizmann Institute for Science in Israel. Subsequently, he received an Executive M.B.A. from the Technion, Israel Institute of Technology. Dr. Daniely co-founded Israel’s first M.B.A. program specializing in Biomedical Management at the College of Management Academic Studies (Rishon Letzion, Israel) and has served as the program’s director since its inception.
Mr. Cohen was appointed as Yissum’s CFO at the end of 2010. Prior to that, he served as Yissum’s controller since 2006. Previous experience includes the Finance department of the Jewish Agency and KPMG Somekh Chaikin, accounting firm. Mr. Cohen is a certified public accountant (Israel) and holds a BA degree in Business Management and Accounting and MBA (Cum Laude), both from the Israeli College of Management.
Dr. Goldwaser serves as VP, Head of Research Collaborations of Yissum & Business Development Manager of the Institute of Drug Research of the School of Pharmacy of the Hebrew University of Jerusalem (IDR). Dr. Goldwaser's career in the bio-pharmaceutical industry began over a decade ago, spanning executive and R&D management roles in the biotechnology, chemical and biological drug development markets. Dr. Goldwaser served as CEO of NasVax from its foundation in 2004 and later as president until April 2010. Dr. Goldwaser joined NasVax from Sol-Gel Technologies, where he served as CTO and Chief Biologist and R&D Project Manager overseeing the Company's experiments, worldwide collaborations, IP management, R&D and drug-candidate evaluation. Prior to that, Dr. Goldwaser worked as Lapid Pharmaceuticals' R&D Manager and Supervisor from 1999 through 2002. Dr. Goldwaser earned his Ph.D. degree in Biological Chemistry from the Weizmann Institute of Science, Rehovot, Israel, his M.Sc. in Medicinal Science from the Sackler School of Medicine, Tel Aviv, Israel, and a B.Sc. in Chemistry from the Hebrew University, Jerusalem, Israel. He is the co-owner of several registered patents of pharmacology and has authored numerous publications in this field.
Tamir Huberman joined Yissum in 2004, he is VP Business Development in the field of computer science and is further responsible for the technical infrastructure necessary to support Yissum’s business processes and application systems. In addition, he is also the IT Director at ITTN; the Israeli Technology Transfer Organization, InnerEye and BriefCam. Prior to joining Yissum, Mr. Huberman was the co-founder of Artigon, served as part of the R&D team at Orgenics and as the Head of IP and R&D at MedisEl. He holds an MSc. in structural biology and a BSc. in biology from the Hebrew University, a diploma in computer & electronics and has continued his MBA studies at the Hebrew University. He is also a certified Trainer of NLP from ABNLP. (LinkedIn Profile: http://il.linkedin.com/in/tamirhuberman/)
Mr. Trachtenberg joined Yissum in 2006 as general counsel, and is responsible for all legal aspects of Yissum’s activities, including technology licensing and intellectual property protection. An attorney with over 25 years of experience in the US and Israel, Mr Trachtenberg previously served as general counsel of Keryx Biopharmaceuticals (NASDAQ: KERX) and of Accent Software International He has a J.D. from New York University and a B.A. from the State University of New York at Binghamton.